United States· US:55513-224_7e0a4bc5-9a5f-4b66-ab41-a4417988ccc2
Riabni
A rituximab product containing rituximab, registered in United States by Amgen, Inc. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Rituximab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FA01 (rituximab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Rituximab · ATC L01FA01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rituximab costs, country by country.
Normalised to the WHO defined daily dose (67 mg), the median price runs from $3.15 in Finland to $96.14 in Switzerland — a ×31 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rituximab · price per daily dose (67 mg)
USD · FX 28 Sept 2026
- CH Switzerland$96.14
- FI Finland$3.15
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RITUXIMAB
- Manufacturer
- Amgen, Inc
- Country
- United States (US)
- ATC code
- L01FA01
- ATC class
- Rituximab
- Defined daily dose
- 67 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1155513-224-01
- ndc1155513-224-21
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for rituximab.
Graded by severity as the source publishes them — 32 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rituximab · interactions on record
81 records
- 32 severe
- 42 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rituximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandMabThera 100 mg/10 ml, Konzentrat zur Herstellung einer InfusionslösungRoche Pharma (Schweiz) AG
- FinlandBlitzimaCelltrion Healthcare Hungary Kft.
- United KingdomItuxredi 100mg/10ml concentrate for solution for infusion vialsDr Reddy's Laboratories (UK) Ltd
- CzechiaBLITZIMACelltrion Healthcare Hungary Kft., Budapest
- BelgiumBlitzima 100 mgCelltrion Healthcare Hungary
- SwedenBlitzima 100 mg Koncentrat till infusionsvätska, lösningCelltrion Healthcare Hungary Kft
- NetherlandsBlitzima 100 mg, concentraat voor oplossing voor infusieCelltrion Healthcare Hungary Kft.
- IcelandBlitzimaCelltrion Healthcare Hungary Kft.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ituxredi
- Iceland · Blitzima, Mabthera
- Liechtenstein · Blitzima, Mabthera
- Norway · Blitzima, Mabthera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f7a8f891-1f04-406f-9e8d-0f974b97747f GET /v1/drugs/f7a8f891-1f04-406f-9e8d-0f974b97747f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "100",
"substance": "RITUXIMAB",
"productndc": "55513-224",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/10mL",
"application_number": "BLA761140",
"marketing_category": "BLA"
}See everything about rituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.